Please assess the completion status of the following clinical trial:

Trial Title: Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic fibrosis patients homozygous for the F508del mutation as confirmed by a genetic test~* Aged 14 years and older~* Male and female~* FEV1 \>50% of predicted normal~Exclusion Criteria:~* Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of visit 1~* Any condition prohibiting the correct measurement of the NPD~* Active or passive smoking~* Planned treatment or treatment with another investigational drug or therapy within 1 month prior to randomisation

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- baseline (Type: NO_INTERVENTION): visit 1
- Vardenafil (Type: ACTIVE_COMPARATOR): nasal instillation of Vardenafil ( visit 2 or 3)
- Placebo (Type: PLACEBO_COMPARATOR): Nasal instillation of placebo (visit 3 or 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).